Human parvovirus B19 infection in blood donors: a meta-analysis / 中国输血杂志

ABSTRACT

【Objective】 To analyze the current situation of human parvovirus B19 infection in blood donors in different regions of China, so as to provide basis for formulating reasonable screening programs of B19 virus for blood donors in various cities and regions. 【Methods】 The literatures related to human parvovirus B19 infection in whole blood and plasma donors published from 1998 to 2021 were searched in the database, and meta-analysis of literatures that satisfied the inclusion criteria was conducted by R4.1.0 software. 【Results】 A total of 35 literatures were obtained, 20 literatures involving 56 846 blood donor samples and 8 literatures involving 1 608 pooled raw plasma samples were subjected to Meta analysis of the positive rates of B19 DNA; 17 literatures involving 12 308 blood sample were subjected to the Meta analysis of the positive rate of B19 IgG antibody.The positive rates of B19 DNA in blood donors(I2=96%, τ2=0.026 0, P<0.01)and pooled raw plasma (I2=98%, τ2=0.124 5, P<0.01), as well as the positive rate of B19 IgG antibod (I2=98%, τ 2 =0.021 0, P < 0.01) presented significant heterogeneity between regions. The combined positive rate of B19 DNA was estimated to be 2.0% (95%-CI: 0.007~0.039), that of pooled raw plasma for production was 66.6% (95%-CI: 0.476~0.832), and that of B19 IgG antibody was 30.2% (95%-CI: 0.246~0.357). 【Conclusion】 Low HPV B19 infection rate and high positive rate of IgG antibody were found in blood donors. Therefore, the risk of B19 virus infection due to blood transfusion is low, but B19 infections in blood donors varied significantly between regions. Domestic cities and regions should reasonably evaluate their own B19 virus infection status to formulate appropriate B19 virus screening programs for blood donors, so as to reduce blood transfusion transmitted risk of B19 virus. In addition, the infection rate of B19 virus in pooled plasma for production is somewhat high. Recipients should be screened for B19 virus antibodies, and appropriate blood transfusion schemes should be formulated for blood recipients lacking neutralizing B19 IgG antibodies to reduce the exposure of B19 virus.